Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111124
Status:
COMPLETED
Last Update Posted:
2013-05-15
First Post:
2005-05-17
Brief Title:
Enbrel in Psoriatic Arthritis
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
Enbrel in Psoriatic Arthritis
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is testing the effect of etanercept in treating both the skin and joint symptoms of psoriatic arthritis patients Enbrel also known as etanercept has already been approved by the Federal Food Drug Administration for the treatment of psoriatic arthritis It is taken as an injection under the skin Participants in the trial will be offered etanercept free of charge to be self-injected once weekly for 24 weeks During that period they will have 5 appointments at the study center and will also be asked to complete assessments of their health
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None